<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04654208</url>
  </required_header>
  <id_info>
    <org_study_id>A5481158</org_study_id>
    <secondary_id>SIRI</secondary_id>
    <nct_id>NCT04654208</nct_id>
  </id_info>
  <brief_title>Swedish Ibrance Registries Insights (SIRI)</brief_title>
  <acronym>SIRI</acronym>
  <official_title>Palbociclib Treatment Patterns in Swedish Patients With Metastatic Breast Cancer - Swedish Ibrance Registries Insights (SIRI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      The main objectives of this study are to describe patient characteristics, treatment patterns&#xD;
      and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients on treatment</measure>
    <time_frame>01 January 2017 until 30 September 2020</time_frame>
    <description>Proportion of patients who have not discontinued treatment will be assessed at various timepoints (Time Frame: treatment start date through end of study [assessed up to 48 months])</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients alive</measure>
    <time_frame>01 January 2017 until 30 September 2020</time_frame>
    <description>Proportion of patients alive on palbociclib combination treatment at different points in time (Time Frame: treatment start date through end of study [assessed up to 48 months])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the demographic and clinical characteristics of the patient population receiving palbociclib combination treatment</measure>
    <time_frame>01 January 2017 until 30 September 2020</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Malignant Neoplasm of Breast</condition>
  <arm_group>
    <arm_group_label>HR+/HER2- locally advanced or MBC in combination with an aromatase inhibitor (AI)</arm_group_label>
    <description>Group Description: patients with at least one filled prescription of palbociclib (ATC (anatomic therapeutic chemical classification system ) code: L01XE33)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HR+/HER2- locally advanced or MBC cancer in combination with fulvestrant</arm_group_label>
    <description>Group Description: patients with at least one filled prescription of palbociclib ATC (code: L01XE33)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>palbociclib</intervention_name>
    <description>patients on palbociclib combination treatment</description>
    <arm_group_label>HR+/HER2- locally advanced or MBC cancer in combination with fulvestrant</arm_group_label>
    <arm_group_label>HR+/HER2- locally advanced or MBC in combination with an aromatase inhibitor (AI)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include all adult (age ≥18 years) patients (male and female) with&#xD;
        at least one filled prescription of palbociclib (ATC code: L01XE33) registered in the&#xD;
        Swedish Prescribed Drug Register between January 1st, 2017 and June 30th 2020.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must meet all of the following inclusion criteria to be eligible for inclusion in&#xD;
        the study:&#xD;
&#xD;
          1. One or more (≥1) filled prescription of palbociclib (ATC code: L01XE33)&#xD;
&#xD;
          2. Age ≥18 years at index date&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        There are no exclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pfizer AB</name>
      <address>
        <city>Sollentuna</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=A5481158</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 27, 2020</study_first_submitted>
  <study_first_submitted_qc>November 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic breast cancer (MBC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

